Dive into a collection of expert insights

This resource hub brings together the latest insights, research

findings, and expert perspectives on Sarcomatrix.

Media

Transforming Lives Through Muscle Science

Explain Sarcomatrix’s commitment to muscular
dystrophy research, care, and support.

Sarcomatrix Therapeutics Launches Regulation D Offering to Advance Novel Oral Muscle Disease Therapy

April 22, 2025

Sarcomatrix Renews EU Orphan Drug Status for LAMA2-RD and Expands Research into Duchenne Muscular Dystrophy Treatment

February 19, 2025

Exploring Innovations in Muscle Wasting Disease Treatment

January 23, 2025

Sarcomatrix Therapeutics and Celito Tech Announce Strategic Collaboration to Advance S-969 to the Clinic

January 7, 2025

Sarcomatrix to Present at Three Major Events During JPM Week 2025 in San Francisco

January 6, 2025

Sarcomatrix Therapeutics Strengthens Leadership Team with Appointment of Al Swarts as Chief of Technical Operations

January 2, 2025

Sarcomatrix Therapeutics AwardedPrestigious “Startup Spotlight” at BIO-Europe2024

September 27, 2024

Sarcomatrix Selected as One of 10 Companies to Present at Startup World Cup Regional, sponsored by Pegasus Tech Ventures

September 9, 2024

Sarcomatrix Advances Lead Compound S-969 to Large Animal Studies for Muscular Dystrophy

May 13, 2024

Understanding Sarcopenia: The Crucial Role of Declining α7β1 Integrin Expression in Aging Muscles.

December 12, 2023

How upregulating α7β1 integrin might compensate for the lack of dystrophin and DGC in individuals living with Duchenne or Beckers Muscular Dystrophy.

December 12, 2023

Sarcomatrix Therapeutics Corp.’s exclusive research Partner Strykagen Awarded SBIR Phase 2 Grant from the National Institutes of Health (NIH) to advance small molecules promoting muscle regeneration.

December 12, 2023

Laminin-111 is a potential first-in-class protein replacement therapy directed to LAMA2-Related Dystrophies – patients, currently in investigational preclinical studies

March 14, 2023

Dive into a collection of expert insights

Media

Transforming Lives Through Muscle Science

Sarcomatrix Therapeutics Launches Regulation D Offering to Advance Novel Oral Muscle Disease Therapy

Sarcomatrix Renews EU Orphan Drug Status for LAMA2-RD and Expands Research into Duchenne Muscular Dystrophy Treatment

Exploring Innovations in Muscle Wasting Disease Treatment

Sarcomatrix Therapeutics and Celito Tech Announce Strategic Collaboration to Advance S-969 to the Clinic

Sarcomatrix to Present at Three Major Events During JPM Week 2025 in San Francisco

Sarcomatrix Therapeutics Strengthens Leadership Team with Appointment of Al Swarts as Chief of Technical Operations

Sarcomatrix Therapeutics AwardedPrestigious “Startup Spotlight” at BIO-Europe2024

Sarcomatrix Selected as One of 10 Companies to Present at Startup World Cup Regional, sponsored by Pegasus Tech Ventures

Sarcomatrix Advances Lead Compound S-969 to Large Animal Studies for Muscular Dystrophy

Understanding Sarcopenia: The Crucial Role of Declining α7β1 Integrin Expression in Aging Muscles.

How upregulating α7β1 integrin might compensate for the lack of dystrophin and DGC in individuals living with Duchenne or Beckers Muscular Dystrophy.

Sarcomatrix Therapeutics Corp.’s exclusive research Partner Strykagen Awarded SBIR Phase 2 Grant from the National Institutes of Health (NIH) to advance small molecules promoting muscle regeneration.

Laminin-111 is a potential first-in-class protein replacement therapy directed to LAMA2-Related Dystrophies – patients, currently in investigational preclinical studies

Invest in a Better Tomorrow

Together, We Can Cure Muscle-Wasting Diseases